Characteristics of Depression Remission and Its Relation With Cardiovascular Outcome Among Patients With Chronic Heart Failure (from the SADHART-CHF Study)

Depression is prevalent in patients with heart failure and is associated with a significant increase in hospitalizations and death. Primary results of the Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) trial revealed that sertraline and placebo had comparable...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2011-02, Vol.107 (4), p.545-551
Main Authors: Jiang, Wei, MD, Krishnan, Ranga, MD, Kuchibhatla, Maragatha, PhD, Cuffe, Michael S., MD, Martsberger, Carolyn, PhD, Arias, Rebekka M., BS, O'Connor, Christopher M., MD
Format: Article
Language:English
Subjects:
Adult and adolescent clinical studies
Aged
Antidepressive Agents - therapeutic use
Biological and medical sciences
Cardiology
Cardiology. Vascular system
Cardiovascular
Cardiovascular disease
Chronic Disease
Clinical medicine
Clinical outcomes
Controlled Clinical Trials as Topic
Depression
Depression - complications
Depression - diagnosis
Depression - drug therapy
Depression - mortality
Female
Heart
Heart failure
Heart Failure - complications
Heart Failure - diagnosis
Heart Failure - drug therapy
Heart Failure - mortality
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Humans
Inpatients - statistics & numerical data
Male
Medical sciences
Mental depression
Middle Aged
Miscellaneous
Mood disorders
Personality Inventory
Prevalence
Psychiatric Status Rating Scales
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Remission Induction
Research Design
Sertraline - therapeutic use
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Depression is prevalent in patients with heart failure and is associated with a significant increase in hospitalizations and death. Primary results of the Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF) trial revealed that sertraline and placebo had comparable effects on depression and cardiovascular outcomes. In this study, we explored whether remission from depression was associated with better survival and aimed to characterize participants who remitted during the trial. Based on depression response during the 12-week treatment phase, SADHART-CHF participants were divided into 2 groups: (1) remission, defined as participants whose last measured Hamilton Depression Rating Scale (HDRS) score was
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2010.10.013